SST3-selective potent peptidic somatostatin receptor antagonists

AUTOR(ES)

Reubi, Jean Claude

FONTE

The National Academy of Sciences

RESUMO

A family of octapeptide derivatives of somatostatin cyclized via a disulfide bridge (des-AA1,2,4,5,12,13[d-2Nal8]-somatostatin-14, ODN-8) was identified that has high affinity and selectivity for the human sst3 somatostatin receptor subtype transfected in CCL39 cells. The binding affinity of carbamoyl-des-AA1,2,4,5,12,13[d-Cys3,Tyr7,d-Agl8(Me,2-naphthoyl)]-somatostatin-14 (sst3-ODN-8) is equal to that of somatostatin-28 for sst3 and less than one-thousandth that for the other four somatostatin receptor subtypes. Compound sst3-ODN-8 potently reverses the somatostatin-28-induced inhibition of forskolin-stimulated cAMP production (pKB = 9.07) and reverses the somatostatin-28-induced stimulation of phospholipase C activity (pKi = 9.22) in sst3-transfected CCL39 cells. [125I-Tyr7]sst3-ODN-8 selectively labels sst3-expressing cells with subnanomolar binding affinity (KD = 0.27 nM). With the use of this radioligand, sst3-expressing human tumors, particularly inactive pituitary adenomas, can be identified with receptor autoradiography; moreover, areas of the human lymphoreticular system express sst3 binding sites selectively displaced by nanomolar concentrations of sst3-ODN-8. Based on the structure–activity relationship of selected analogs substituted at positions 3, 7, and 8, we hypothesize that the basis for sst3 selectivity, high affinity, and possibly antagonism resides in the ring size of the analog and the unique conformational and structural character of the N-methylated amino-2-naphthoyl side chain of aminoglycine at position 8 and not in the Tyr7 substitution or in the d-configuration at position 3. The family of labeled and unlabeled sst3-ODN-8 analogs represents highly innovative, potent, and specific sst3-selective antagonist tools for the study of sst3-mediated physiological and pathophysiological conditions that may suggest novel clinical applications.

Documentos Relacionados

• Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2
• Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): Development of CRFR2β-selective antisauvagine-30
• Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.
• Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells.
• [Phe4]somatostatin: a potent, selective inhibitor of growth hormone release.